Subscribe
Close
  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Renew

Germany-Based Nanion Expands U.S. Operations with Newark, California Center

08/27/2018
Germany-based Nanion, a leading provider of instrumentation for ion channel drug discovery and screening, expanded its U.S. operations with the opening of a new hub in the Newark, California.

The new office recently opened in a state-of-the-art incubator site strategically located in Silicon Valley where several innovative start-ups and small companies work together in a vibrant ecosystem of collaboration, company officials said.

Rodolfo Haedo Senior Vice President North America, says, "I am delighted to see Nanion continue to grow so rapidly in the US. As we expand to the West Coast, we can further strengthen the focused and attentive customer support that has helped build our success.”

“As the sales of our SyncroPatch 384/786PE HTS systems have substantially increased over the last years, we have decided to expand both our infrastructure and personnel in this region full of young energetic startup companies,” he said. “In addition to the office and new West Coast Field Application Scientist position, we anticipate future employment opportunities in order to help support and foster the rapidly increasing customer base. We are all very much looking forward to this new phase we are entering at Nanion."

Dr. James Costantin, Director of Customer Relations, continues, "The proximity of Nanion's West Coast office to the rapidly expanding presence of pharmaceutical companies heavily investing in both the South San Francisco and San Diego regions makes the West Coast office ideally situated to serve our customers.”

“In addition to providing office space to serve our customers, the new location allows Nanion to provide rapidly responding Application Support across all US time zones. We are driven to ensure that our customers succeed at all levels of their ion channel Drug Discovery endeavors, including Assay Development, Screening Campaigns, SAR/Medicinal Chemistry, and Counter Screening. Our customer's success is extremely important to us, as it is how we measure our success,” he added.

Exclusive Research